Overview

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Status:
RECRUITING
Trial end date:
2028-05-29
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Phase:
PHASE3
Details
Lead Sponsor:
Amgen
Treatments:
pembrolizumab